u/Ancient_Bobcat_9150 · 15h ago1 prior · awaiting results
Boston Scientific: Too soon to catch a falling knife?
Boston Scientific trades at a 14x forward P/E—a discount to the historical 20x–25x range for high-moat medtech—while growing organic sales at 7% and adjusted EPS at 15% YoY. Management is competent, actively shareholder-friendly via buybacks, and the company remains well-positioned in mission-critical markets despite near-term cyberattack-driven headwinds.
At post $43.10Now $43.100.0% since postedas of Sep 10, 4:30 PM ET